In selected DLBCL subtypes with aberrant toll-like receptor (TLR) signaling, IRAK4 inhibitors may have clinical utility, either alone or in combination with BTK or BCL2 inhibitors [233], with capacity to inhibit the expression of PD-L1 and provide novel opportunities for hematologic malignancies [234]. This evidence concerns the gene CD274 and diffuse large B-cell lymphoma.